Dr. Bruce Forrest serves as the President of Hudson Innovations, LLC, and as Co-Head of Life Sciences Investment Banking, Young America Capital, LLC. Dr. Forrest received his MD at the University of Adelaide, Australia, in 1991. He possesses over 25 years of global leadership in pharmaceutical development with expertise in, but not limited to, vaccines and biopharmaceuticals development in both major and emerging markets. During his career in the pharmaceutical and medical device industry, Dr. Forrest was the clinical leader for several major vaccine programs, including a meningococcal C conjugate vaccine; a live, rotavirus vaccine; a pneumococcal conjugate vaccine; and a live attenuated influenza vaccine. As a Senior Vice President at Wyeth Pharmaceuticals, Bruce was responsible for all late-phase development activities in Wyeth Vaccines Research. He led both clinical and pharmaceutical science development, including Fermentation and Process Development, Analytical Development, Formulation Development, GMP testing, Development Project Management, GMP Clinical Supplies Manufacturing and Distribution, Outsourcing Management, and Development Finance.
In addition, Bruce Forrest has extensive experience and field knowledge of the pharmaceutical development environment in Asia, especially Japan, where he served as Board Member, Corporate Officer, and Executive Director (Head) of R&D for Wyeth K.K. He oversaw the local product approvals for etanercept and gemtuzumab ozogamicin, as well as product registration submissions for a pneumococcal conjugate vaccine, bazedoxifene, temsirolimus, venlafaxine, and tigecycline; and, was responsible for developing a successful strategy for the integration and coordination of development activities across the major markets in East Asia.
Expertise: Advanced vaccine development and commercialization